A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome
Journal of Child and Adolescent Psychopharmacology · 2025
DOI: 10.1089/cap.2024.0124 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2025. Verfasst von Robyn P Thom und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lurie Center for Autism, Lexington, MA, USA. Hauptthemen laut MEDLINE: Anti-Anxiety Agents, Anxiety, Buspirone, Williams Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lurie Center for Autism, Lexington, MA, USA.
- Massachusetts General Hospital, Boston, MA, USA.
- McLean Hospital, Belmont, MA, USA.
ORCID-Profile: Robyn P Thom
Zitieren
APA
Thom, R. P., Renzi, D., Pecukonis, M., Mullett, J., Ravichandran, C., & McDougle, C. J. (2025). A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2024.0124
Vancouver
Thom RP, Renzi D, Pecukonis M, Mullett J, Ravichandran C, McDougle CJ. A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome. Journal of Child and Adolescent Psychopharmacology. 2025. doi:10.1089/cap.2024.0124
BibTeX
@article{Thom2025,
author = {Thom, Robyn P and Renzi, Danielle and Pecukonis, Meredith and Mullett, Jennifer and Ravichandran, Caitlin and McDougle, Christopher J},
title = {A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2025},
doi = {10.1089/cap.2024.0124}
}
EUVIMED